Touchlight unveils next-gen circular DNA portfolio for advanced gene therapies
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Subscribe To Our Newsletter & Stay Updated